News

Vect-Horus Nominated for the 2024 Biotech Trophy Award, Organized by France Biotech

Vect-Horus, a privately held biotechnology company that designs and develops molecular vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced it has been nominated for the 2024 Biotech Trophy (…)


Vect-Horus Enters Exclusive License Agreement with Ionis Pharmaceuticals to Advance Systemic Delivery of RNA-Targeted Medicines for Neurological Diseases

Vect-Horus, a privately held biotechnology company that designs and develops molecular vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced it has entered into a global license agreement with (…)


Happy new year !

The Vect-Horus teams join to wish you a Happy Holiday season and Best Wishes for 2024.


Meet Vect-Horus at BIOTECH SHOWCASE, San Francisco, January 8-10, 2024

From January 8 to 10, Emmanuelle Bettendorf will participate in the #BiotechShowcase at #JPM24 and will be available to meet with you on partnership opportunities.


Vect-Horus Enters Exclusive License Agreement with Novo Nordisk to Develop Targeted Therapeutics

Vect-Horus, a privately held biotechnology company that designs and develops vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced it has entered into a global license agreement with Novo (…)


Meet Vect-Horus at OTS, Barcelona, October 22-25, 2023

Vect-Horus team will attend the 19th Annual Meeting of the Oligonucleotide Therapeutics Society from October 22nd to 25th, 2023, in Barcelona.
We are pleased to announce that Guillaume Jacquot, Program Director, Brain & Tissue Targeting of (…)


Vect-Horus will join the Single-Domain Antibodies Summit

Vect-Horus Vector Discovery Team will attend the Single Domain Antibodies Summit that will be held in Paris from 18th to 20th of September 2023.
Interesting sessions are planned and Vect-Horus will attend the one dedicated to “Single domain (…)


Early September VECT-HORUS’ team will be attending the EANM2023 Annual Congress!

On this occasion, our partner Radiomedix, Inc. , was selected to present an update of our joint research program. This talk untitled “Glioblastoma and Pancreatic Adenocarcinoma - Versatile radiolabeled probe targeting Low Density Lipoprotein (…)


Meet Vect-Horus at 3rd Oligonucleotides for CNS Summit in Boston June 6-8th, 2023

Meet with Michel KHRESTCHATISKY and Guillaume JACQUOT at the 3rd Oligonucleotides for CNS Summit 2023, dedicated to optimizing antisense and RNA chemistry for brain delivery, in Boston from June 6-8th, 2023.


Meet Vect-Horus at BIO International in Boston June 5-8, 2023

Emmanuelle BETTENDORF, Sr Business Developer, will attend Bio International Convention.


Vect-Horus Appoints Dr Jean-Manuel PEAN as Chief Scientific Officer

Marseille, April 3rd, 2023 - VECT-HORUS, a biotechnology company that designs and develops vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced the appointment of Dr Jean-Manuel Péan as Chief (…)


Vect-Horus participates to the event Radiopharmaceuticals & Imaging on March 14, 2023

Cedric MALICET, Oncology Department Manager, will participate to the Radiopharmaceuticals & Imaging event next week ! You can book a meeting with him directly via the partnering system to discuss company developments on its theranostic agents.


Meet Vect-Horus at BIO Spring Basel, Switzerland, March 20–22, 2023

Emmanuelle BETTENDORF will participate in BioEurope Spring from March 20 to 22, 2023 and will be available to meet with you on partnership opportunities.


Vect-Horus will be attending the BiotechShowcase 23

From January 18 to 19, Emmanuelle Bettendorf will participate in the virtual #BiotechShowcase at #JPM23 and will be available to e-meet with you on partnership opportunities.


Meet Vect-Horus at TIDES Europe in Vienna from November 16th to 18th, 2022.

Guillaume JACQUOT will share a presentation on “Targeted delivery of Therapeutic Oligonucleotides to CNS by systemic administration” a good opportunity for Vect-Horus to present its last results.
Emmanuelle BETTENDORF will be there as well to (…)


RadioMedix and Vect-Horus announce first dosing of Glioblastoma Multiforme and Pancreatic ductal adenocarcinoma patients with 68Ga-RMX-VH

Houston, TX, USA and Marseille, France, Nov. 15, 2022 (GLOBE NEWSWIRE) — RadioMedix and Vect-Horus are pleased to announce that they have successfully dosed the first patients in an exploratory Investigational New Drug (eIND) application to (…)


Vect-Horus will be attending BIO Europe from the 24th - 26th October in Germany

This is the first in person BIOEurope since 2019 and we are excited to meet everyone face-to-face again.
Feel free to connect with Emmanuelle BETTENDORF on the platform for a meeting/coffee to discuss our DrugDelivery platform, amongt others in (…)


Vect-Horus will attend the Biorezo “Nouvelles technologies de vectorisation, perspectives pour les biotechs et pharma”

We are pleased to announce that Marion DAVID will be giving a talk entitled “Développement de vecteurs moléculaires pour l’adressage ciblé de molécules d’intérêt thérapeutique” during the Biorezo organized by Eurobiomed in Toulouse on October 18th.


Vect-Horus will be attending the #EANM 2022 Annual Congress

Great occasion to assist to valuable conferences about Nuclear Medicine, Molecular Imaging, Optimization of Radiolabeled Biomolecules in one of the most valuable Nuclear Medicine event in Europe.
Meet with Cedric MALICET, PhD during the EANM on (…)


Vect-Horus will participate to the HealthTech Innovation Days on November 13-14, 2022

Elodie DORMES, Business Development Manager, will attend the HealthTech Innovation Days in Paris on November 13-14, 2022.
2 days dedicated to networking and interaction with Biotech and Pharmaceutical companies.


Vect-Horus reçoit une subvention pour le développement de sa plateforme VECTrans® dans le domaine de l’ophtalmologie

MARSEILLE, France—Vect-Horus, une société de biotechnologie qui conçoit et développe des vecteurs permettant l’adressage ciblé de molécules thérapeutiques et d’agents d’imagerie vers différents organes dont le cerveau, annonce l’accord de (…)


Vect-Horus will participate to the “R&D Seminar IMAGING 2022” organized by the Cerimed September 26-30, 2022

VECT-HORUS S.A.S. will participate in the next event dedicated to Imaging and organized by CERIMED: “R&D Seminar IMAGING 2022” from Monday, 26th September to Friday 30th September.
Cedric MALICET will give a talk, « From bench to Clinic », (…)


Meet Vect-Horus at BIO International in San Diego June 14-18, 2022

Elodie DORMES, Sr Business Development Manager, will attend Bio International Convention.


Vect-Horus will present at Delivery of Macromolecules, June 8, 2022

Guillaume JACQUOT, Head of Intracellular Trafficking & Translational Research, will give a talk on this occasion.


Vect-Horus strengthens its scientific advisory board with the appointment of Frédéric MATONTI

Vect-Horus extends its Scientific Advisory Board with the expertise of Frédéric Matonti, a Leading Ophthalmology Specialist.


3rd Annual RNAi-Based Therapeutics Summit from April 19th to 21th, 2022, in Boston

Michel KHRESTCHATISKY, Scientific Counsel, will have a talk entitled “Development of Molecular Vectors for Targeted Delivery of RNAi” and Elodie DORMES, Sr BD Manager, will also be there and pleased to meet you in person during the summit.


Vect-Horus strengthens its scientific advisory board with the appointment of Dr. Julia ALTERMAN

Vect-Horus extends its Scientific Advisory Board with the expertise of Dr. Julia Alterman on siRNA chemical modification for extra-hepatic delivery.


e-Meet Vect-Horus at the digital BIO Europe Spring from March 28 to 31, 2022

Emmanuelle BETTENDORF will participate in BioEurope Spring from March 28 to 31, 2022 and will be available to meet with you on partnership opportunities.


Vect-Horus will participate to the event “Espace & Santé” co-organized by CNES, Region Paca and DHUNE on March 29, 2022

Michel KHRESTCHATISKY will be part of the roundtable 4 and will present the company latest results in connection with “Maintaining and increasing performance – intelligent human machine interfaces, brain tech, exoskeletons, human factor, (…)


Vect-Horus reçoit un financement non dilutif de 1M(e) dans le cadre du dispositif de relance Européen REACT-EU

Vect-Horus annonce l’accord de la Région SUD Provence-Alpes-Côte d’Azur pour une subvention de plus d’un million d’euros.


Séminaire M&M’s – Muscle Monday Seminars of the Institute’s Myology Centre for Research on January 17, 2022

Michel Khrestchatisky (CNRS Research Director, Director of the Institute for Neurophysiopathology) Co-Founder & Scientific Counsel of Vect-Horus presents "Development of molecular vectors for targeted delivery of RNAi via receptor-mediated (…)


BiotechShowcase

Meet Vect-Horus at the first 2022 partnering event from January 17th to January 19th, during the digital week.


Happy new year !

The Vect-Horus teams join to wish you a Happy Holiday season and Best Wishes for 2022.


Meet Vect-Horus at BIO Europe Digital

Emmanuelle BETTENDORF will participate in BioEurope from October 25 to 27, 2021 and will be available to meet with you on partnership opportunities.


Vect-Horus will attend to BioJapan Digital Conference

Elodie DORMES, BD Manager, will attend to the BioJapan Digital Conference, starting the 12th of October 2021 and ending the 15th of October. 4 days dedicated to digital networking and interaction with Biotech and Pharmaceutical companies needing (…)


LDL receptor-peptide conjugate as in vivo tool for specific targeting of pancreatic ductal adenocarcinoma

Vect-Horus is proud to be part of the research in PDAC with its theranostic agents to first improve PDAC diagnosis, response monitoring or recurrence detection in operated patients and also treat them.
Cedric malicet, Oncology Department (…)


Vect-Horus and RadioMedix Announce FDA Approval of Exploratory IND of Diagnostic 68 Ga-RMX-VH in Glioblastoma Multiforme

Vect-Horus and RadioMedix are pleased to announce the FDA clearance of eIND application to evaluate 68Ga-RMX-VH for the diagnostic of GBM.


NTSR2 is induced in astrocytes and brain endothelial cells in relation to neuroinflammation following pilocarpine-induced seizures in rats

Neurotensin (NT) acts as a primary neurotransmitter and neuromodulator in the CNS and has been involved in a number of CNS pathologies including epilepsy. NT mediates its central and peripheral effects by interacting with the NTSR1, NTSR2, and (…)


Meet Vect-Horus at BIO International

Elodie DORMES will attend Bio International Convention in June 10-18, 2021.


Vect-Horus attends to the NLSDays

Connect with Emmanuelle BETTENDORF Sr. Business Developer at this year’s digital NORDIC LIFE SCIENCES through the event’s One-on-One Partnering.


e-Meet Vect-Horus at the digital BIO Europe Spring

Emmanuelle BETTENDORF will participate in BioEurope Spring from March 22 to 25, 2021 and will be available to meet with you on partnership opportunities.


TIDES Asia, March 2-5 2021 - 100% Virtual

Guillaume JACQUOT PharmD, PhD, will present last company results on extra-hepatic delivery of oligonucleotides.


Oligonucleotides for CNS Congress from February 22-24, 2021

Dr Michel KHRESTCHATISKY will join the session dealing with “Exploring Extra-Hepatic Delivery to Relevant Targets within the CNS & Muscle” and give a talk to describe the use of VECT-HORUS “Molecular Vectors for Targeted Delivery of (…)


Vect-Horus completes its €12 Million fund-raising operation

Vect-Horus completes its Series D with private investors for a total amount of € 12 million to strengthen company’s effort in identification of new vectors, development of theragnostic agents and delivering of biologics and nucleic acids.


Happy new year !

May the upcoming year fill your life with great achievements, personally and professionally.
The Vect-Horus teams wish you a promising and fulfilling new year.


Vect-Horus and Cerimed announce collaboration to support the development of its theragnostic agents

Vect-Horus is co-developing with Radiomedix one agent which will enter clinical trials in 2021 for the diagnosis of glioblastoma.
With Cerimed, Vect-Horus also pursues the investigations on its other theragnostic candidates targeting the Low-Density Lipoprotein Receptor, which has been shown to be expressed at high levels in some tumours, including pancreatic tumours.


Vect-Horus team will attend the 8AIS2020 symposium from Nov. 23-26, 2020

Marion DAVID will be presenting a poster entitled “Development of versatile single domain antibody vectors that enhance brain deliver of antibodies by targeting the TfR transport system. ”
Please use the partnering system to contact us and (…)


TIDES Europe, Nov. 11-13, 2020 - 100% Virtual

Dr Guillaume JACQUOT will share a presentation on “TfR-targeting VHH Nanobodies for Extra-hepatic Delivery of Oligonucleotides” a good opportunity for Vect-Horus to present its last results.
A live Q&A session will also give the opportunity (…)


VECT-HORUS recognized as a newcomer to the theranostic field by Labiotech

Vect-Horus mentioned as a relative newcomer to the theranostic field with a high potential in “Radiopharmaceuticals Gain Traction for Cancer Theranostics Potential” article by Labiotech - Europe’s Leading Biotech news website.
Full article (…)


Meet Vect-Horus at BIO Europe Digital

Emmanuelle BETTENDORF, Business Developer will attend BIO Europe from 26 – 29 October 2020 in a digital format.
If you are interested to meet and discover VECTrans technology, please use the B2B Partnering system.


New PCT patent application covering anti Transferrin receptor vectors

Vect-Horus has filed a PCT patent application covering a library of vectors that target the Transferrin receptor (TfR). This patent strengthens the intellectual property of the Company with a portfolio containing now 6 patent families. This confirms its position as a major player in Blood-Brain Barrier drug delivery technology.


Vect-Horus raises €6.7 Million to further develop its VECTrans® Platform

Vect-Horus raises €6.7 million to further develop its VECTrans® platform and the clinical trial of its first theragnostic agent.


Blood Brain Barrier Summit delivered digitally

Vect-Horus will assist to the Blood Brain Barrier Summit, delivered digitally from August 31 to September 2nd, 2020


Vect-Horus one the 50 Best Companies to Watch 2020 according to the Silicon Review magazine

A pioneer in drug delivery with an innovative targeting technology: Vect-Horus
Full article available at: https://thesiliconreview.com/magazine/profile/vect-horus-innovative-targeting-technology/


e-Meet Vect-Horus at the digital BIO International

Elodie DORMES will be attending the digital BIO International convention in June 8-12, 2020


Vect-Horus: Top Drug Discovery and Development Europe Companies

Vect-Horus: Innovation to "Bypass" the Barriers
PharmaTechOutlook elected Vect-Horus as one of the ten companies that are at the forefront of providing Drug Discovery and Development solutions and transforming businesses in Europe in 2020. (…)


e-Meet Vect-Horus at the digital BIO Spring Paris

Vect-Horus will attend to the BIO Spring from 23–24 March 2020.
If you are interested to meet, please use the B2B Partnering system.


8th Edition of BioFIT for the first time in MARSEILLE

Vect-Horus will be present at the BioFIT partnering event on December 10th, 2019 in Marseille.


3rd Edition of Translational neuroscience Day : challenges and opportunities

Michel KHRESTCHATISKY co-founder of Vect-Horus – Director of the UMR7051 Institute of Neurophysiopathology at Aix-Marseille University / CNRS will speak at two sessions of The third edition of “Translational neuroscience Day: challenges and (…)


Society for the study of Blood-Brain interfaces SEISC 2019 congres

Stéphane GIRARD will present iPS cell-derived model of the human blood-brain-barrier on Friday 15, Nov Session 1 of the Society for the study of Blood-Brain interfaces SEISC 2019 congres in Paris


TIDES Europe: Oligonucleotide & Peptide Therapeutics in AMSTERDAM

Dr Guillaume JACQUOT will present "Targeted Drug Delivery to the CNS and Peripheral Tissues Using the VECTrans® Innovative Technology" during the TIDES Europe, 12-15 November 2019.


Meet Vect-Horus at BIO Europe HAMBURG

VECT-HORUS will attend BIO Europe from November 11–13, 2019
If you are interested to meet, please use the B2B Partnering system.


Vect-Horus focuses on Target engagement and intracellular delivery of LDLR conjugates to design new targeted drug therapies

Varini et al. J Control Release 2019
Targeted delivery to specific tissues and subcellular compartments is of paramount importance to optimize therapeutic or diagnostic interventions while minimizing side-effects. Using recently identified LDL (…)


Festival of Biologics 2019 in BASEL

Meet with Pascaline LECORCHE during the Festival of Biologics 2019, 15 – 17 October 2019 _ Basel Switzerland and discuss on « Design of peptide-based vectors for targeted delivery ».


Vect-Horus will be attending the EANM’19 Congress in Barcelona

Cedric MALICET PhD, Oncology Project Manager and Elodie DORMES, Business Development Manager will attend EANM from 12-16 October, 2019 in Barcelona to discuss Peptide Receptor Radionuclide Therapy strategy and partnered Vect-Horus’ products.


Meet Vect-Horus at BIO Japan

Dr Jamal TEMSAMANI, Drug Development and Corporate Director will attend BIO Japan from October 9–11, 2019
If you are interested to meet, please use the B2B Partnering system.


Relocation of the company to support its development

Relocation of Vect-Horus in medical faculty of the La Timone campus to maintain strong collaborative working environment with its historical partners and support its development.


Vect-Horus announces Collaboration and Option Agreement with ASTELLAS Pharma

Vect-Horus announced today the signing of the Research Collaboration and Option Agreement (the “Agreement”) with Astellas Pharma Inc., a Japan based pharmaceutical company (“Astellas”). Vect-Horus will use its proprietary technology VECTrans® to (…)


Vect-Horus will attend BIO International Convention in PHILADELPHIA

Vect-Horus will attend BIO US in Philadelphia | June 3-6, 2019.
If you are interested to meet, please use the B2B Partnering system.


Vect-Horus enters into Collaboration and License Agreement with ONO Pharmaceutical Co., Ltd.

Vect-Horus S.A.S. announced today the signing of a collaboration and license agreement with Ono Pharmaceutical Co., Ltd., focused on the development of novel molecules targeting neurodegenerative diseases


AD/PD 2019​ International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders in LISBON

Marion DAVID and Romy COHEN will present the “Development of vectors that cross the blood brain barrier to enhance CNS drug delivery in neurodegenerative diseases” in session A: β-Amyloid Diseases poster n°ADPD9-1832


Meet Vect-Horus at BIO Spring Vienna

VECT-HORUS will attend BIO Europe from March 25–26, 2019
If you are interested to meet, please use the B2B Partnering system.
https://ebdgroup.knect365.com/bioeu...


Nanomedicine for treating cancer and brain diseases symposium in MARSEILLE

In the context of the Euronanomed projects for Action on Nanomedicine under Horizon 2020, a Symposium will be held at the Luminy campus in Marseille on March 8, 2019. Dr. Khrestchatisky will give a talk titled "Molecular vectors for drug delivery (…)


Vect-Horus and RadioMedix announce the signing of a LOI to co-develop a Vect-Horus’ radio-theranostic agent for Glioblastoma

Marseille, France- Houston - March 5, 2019 - Vect-Horus and RadioMedix announced today the signing of a Letter of Intent (LOI) to establish an agreement for the co-development of a Vect-Horus theranostic agent for the diagnostic and radiotherapy (…)


Signature of a Research Common Lab with the Institute for NeuroPhysiopathology (UMR7051 CNRS-AMU)

Since its incorporation in 2005 VECT-HORUS is a leading partner of the French academic institutions CNRS and Aix-Marseille University. Indeed, the company as a spin-off of the NICN (UMR7259 CNRS-AMU) now Institute for NeuroPhysiopathology INP (…)


Vect-Horus announces agreement with Johnson&Johnson Innovation

Vect-Horus announced today the signing of a research collaboration agreement with Janssen Pharmaceuticals, Inc. one of the Janssen Pharmaceutical Companies of Johnson & Johnson.


Meet Vect-Horus at BIO Europe Copenhagen

VECT-HORUS will attend BIO Europe from 5–7 November 2018.
If you are interested to meet, please use the B2B Partnering system.


Vect-Horus will be attending the EANM’18 Congress in Düsseldorf

VECT-HORUS will present a poster on its proprietary technology platform, VECTrans®, for the targeting and delivery of imaging or therapeutic agents to tumors.
Please come and meet Cedric MALICET PhD, Oncology Project Manager.


Vect-Horus raises 3.5M€ to accelerate its development programs

VECT-HORUS, a biotechnology company that designs and develops vectors facilitating targeting of therapeutic molecules and imaging agents, announces completion of a new fund-raising round for 3.5 million euros, following a previous round of 2.5 (…)


BIO International Convention in BOSTON, MA

The BIO International Convention (BIO) attracts 16,000+ biotechnology and pharma leaders who come together for one week of intensive networking to discover new opportunities and promising partnerships.
VECT-HORUS’ business model is to make its (…)


ECMED EU-GliaPhD international conference in MALTA

Michel Khrestchatisky and Grigorios Kyriatzis (Early Stage Researcher, ESR), both members of the ITN Marie Curie project ECMED will participate in the ECMED EU-GliaPhD international conference organized in Malta, April 29 to May 2, 2018. Michel (…)


AAT-AD/PD Focus Meeting, TORINO Italy

Meet Marion DAVID Vect-Horus’ Vector Discovery platform Manager during the AAT-AD/PD Focus Meeting.
This Alzheimer’s disease conference and Parkinson’s disease conference will present all the latest breakthroughs in treatment, translational (…)


Meet Vect-Horus at BIO Spring Amsterdam

VECT-HORUS will attend BIO Spring from 12-14 March 2018.
If you are interested to meet, please use the B2B Partnering system or send an email to Elodie DORMES, Business Development Manager at elodie.dormes(at)vect-horus(dot)com (…)


Vect-Horus demonstrates the high versatility of its peptide-vectors library for a targeted delivery of small molecules and protein cargos

Identification and characterization of highly versatile peptide-vectors that bind non-competitively to the low-density lipoprotein receptor for in vivo targeting and delivery of small molecules and protein cargos.
Marion David, Pascaline (…)


Selected for a 5’ Pitch at the 2nd edition of the TOULOUSE ONCO WEEK

Cédric MALICET, PhD Oncology Project Manager, will present VECT-HORUS’ proprietary technology platform, VECTrans®, that facilitates the targeted delivery of imaging or therapeutic agents to tumors using receptor mediated transport. (…)


Vect-Horus will be attending the J.P. Morgan 36th Annual Healthcare Conference

January 8-11, 2018 – San Francisco, CA, USA
If you would like to arrange a one-on-one meeting with Vect-Horus’ team during the conference, please contact Jamal TEMSAMANI, Director of Drug Development & Corporate at (…)


Gerhard Levy Distinguished Lectureship in Pharmaceutical Sciences for Prof. Scherrmann, chairman of Vect-Horus’ Scientific Advisory Board

University at Buffalo, The State University of New York distinguished Professor Emeritus of Pharmaceutical Sciences Gerhard Levy was a pioneer and leading contributor in the areas of pharmacokinetics and clinical pharmacokinetics.
The Gerhard (…)


Meet Vect-Horus at BIO Europe Berlin

6-8/11/2017
Berlin, Germany
https://ebdgroup.knect365.com/bioeurope/


Vect-Horus confirmed to attend BioPharm America 2017

26-27/09/2017
Boston USA
ebdgroup.knect365.com/biopharm-america/


Vect-Horus announces the expansion of its Scientific Advisory Board

VECT-HORUS is a French biotechnology company that designs and develops peptide-vectors to facilitate the delivery of drugs or imaging agents into the brain and other organs, and in particular in tumours. VECT-HORUS announces the expansion of its (…)


Participation au BIOREZO™ Vectorisation : de l’imagerie à la thérapeutique

Participation au BIOREZO™ VECTORISATION : DE L’IMAGERIE À LA THÉRAPEUTIQUE


Vect-Horus at Pierre Fabre DayOne Open Innovation Day

Vect-Horus selected for an elevator pitch during DAYONE 2017: an open innovation day dedicated to pharmaceutical innovation. The one day conference aim is to identify, bring out, and develop innovative projects by biopharmaceutical companies, (…)


Selected for an Elevator Pitch at the 3rd edition of MEET2WIN

Vect-Horus will participate to the MEET2WIN a French Business Convention entirely dedicated to open innovation, collaborative research and technology transfer.
https://www.b2match.eu/meet2win2017/participants/176


CNS Barrier Congress

22-23 March 2017 // Holiday Inn London Kensington Hotel


Vect-Horus raises 2.5 M€ to finance its development projects in the “targeted therapy” field

Marseille, 22 Mars 2017 - The French biotechnology start up VECT-HORUS, a European leader in the design of vectors that facilitate the delivery of drugs into the brain and other organs, announces completion of a new fund raising round for 2.5 (…)


Meet Vect-Horus at BIO Spring Barcelona

March 20-22 // Barcelona, SPAIN


Vect-Horus validates the potential of its peptide vectors to transport proteins or antibodies, across the blood-brain barrier via receptor mediated transport

(Molino et al., 2017, The FASEB Journal)
www.fasebj.org/content/early/2017/01/19/fj.201600827R.abstract


Meet Vect-Horus at BIO Europe Cologne

November 7-9 // Köln, GERMANY


RIB 2016 PARIS – Neurological Disorders

Rendez-vous le 2 novembre 2016, 9h-18h au HUB Bpifrance, 8 Bd Haussmann, 75009 Paris


Vect-Horus receives the Frost & Sullivan 2016 Leadership award

Press release
Communiqué de presse
French biotechnology startup VECT-HORUS, a European leader in the design of vectors that facilitate the delivery of drugs into the brain and other organs, receives the Frost & Sullivan 2016 Leadership (…)


Vect-Horus rejoint la communauté Bpifrance Excellence

L’entrée de la société de « CNS Drug Delivery » dans le cercle très fermé des membres de Bpifrance Excellence récompense l’innovation apportée par sa plateforme VECTrans®


Two new patents protecting VECTrans® technology issued in several major countries

Press release Communiqué de presse
VECT-HORUS, a biotechnology company that designs and develops peptide vectors for addressing drugs or imaging agents to the brain and other organs, announces the strengthening of its patent portfolio with the (…)


Boulder Peptide Symposium

VECT-HORUS to Present at Boulder Peptide Symposium 2015


Biopharm America 2015

VECT-HORUS will be present at Biopharm America 2015.


11th International Conference on Cerebral Vascular Biology

VECT-HORUS is sponsoring the 11th International Conference on Cerebral Vascular Biology (CVB 2015).


Vect-Horus announces the signing of a scientific collaboration agreement with SERVIER

The two companies intend to enter in a collaboration agreement to develop new therapeutic molecules in the field of central nervous system (CNS) diseases
VECT-HORUS, a biotechnology company that designs and develops peptide vectors that (…)


Neurotensin, vectorised by VECT-HORUS, is the first drug-candidate in neuroprotective hypothermia

VECT-HORUS starts the regulatory preclinical development of VH-N439, positioned as a first-in-class neuroprotective agent in brain ischemia Neurotensin is a neuropeptide with global hypothermic potential when administered directly into the brain, (…)


Meet Vect-Horus at BIO-Europe Spring® 2015

Meet VECT-HORUSat BIO-Europe Spring® 2015, Paris, France
March 9-11, 2015


Vect-Horus announces the signing of a scientific collaboration agreement with SANOFI in the field of neurodegenerative diseases

The goal of this collaboration is to use VECT-HORUS’ proprietary technology to transport therapeutic antibodies into the brain for the treatment of a neurodegenerative disease.


Meet Vect-Horus at the 36th PAMM-EORTC Winter meeting

Pharmacology and Molecular Mechanisms Group (PAMM) of the European Organisation for Research and Treatment of Cancer (EORTC).
Meet VECT-HORUS at the 36th PAMM-EORTC Winter meeting, Marseille, France
January 21-24, 2015


Vect-Horus announces a new equity issue of 1.5 M€ to finance the preclinical development of its first vectorized product

VECT-HORUS announced today having raised € 1.5 million, from its historical shareholders, mostly professionals in the finance industry. In total, VECT-HORUS raised in 9 years more than € 11 million, of which € 5 million in grants and research tax (…)


Vect-Horus is one of the CNRS 15 success stories

VECT-HORUS was recently identified by the CNRS as one of the 15 success stories in 1,000 companies created from CNRS laboratories.


Vect-Horus appoints Dr Jamal Temsamani as Director of Drug Development & Corporate

VECT-HORUS announced today the appointment of Dr. Jamal Temsamani as Director in charge of Drug Development & Corporate. He will lead the Company’s drug development programs from discovery to early clinical and will be in charge of industrial (…)


Vect-Horus, AAA form scientific collaboration to open new avenues in treatment of brain diseases

The partnership will develop new molecules for the treatment of brain diseases
Vect-Horus, a French company specialized in the development of vector molecules for the central nervous system, announces today it has signed a scientific (…)


Vect-Horus successfully completes the VECtoBrain project

Ths project was supported from 2009 to 2013 by the Agence Nationale de la Recherche (ANR) BiotecS Call 2009.
The project was coordinated by VECT-HORUS (Dr. Guillaume Jacquot) and involved the UMR7259 laboratory (CNRS and Aix-Marseille (…)


Vect-Horus is a partner laureate of the ANR RPIB Call 2013 for proposals

VECT-HORUS is a partner laureate of the Agence Nationale de la Recherche (ANR) RPIB Call 2013 for proposals and will be involved in the VEC2Brain project involving 3 academic laboratories. The project will be coordinated by Dr Michel (…)


Two research groups specialized in CNS drug delivery and in the development of therapeutic strategies for glioblastoma give in vivo POC on one of the peptide vectors described by Vect-Horus

Two groups of the Institute of Hematology, Huazhong University in Wuhan and the Key Laboratory of Smart Drug Delivery, Fudan University in Shanghai, well known and specialized in CNS drug delivery and in the development of therapeutic strategies (…)


Fifth round of funding

VECT-HORUS has completed a fifth round of venture capital funding from private shareholders.


Vect-Horus and its academic partners describe the chemical optimisation of one of its lead peptides (Malcor et al., 2012, J Med Chem)

and publish a review article on CNS drug delivery (Vlieghe and Khrestchatisky, 2012, Med Res Rev).


Vect-Horus is a partner laureate of the ANR MALZ 2011 call for proposals

VECT-HORUS is a partner laureate of the Agence Nationale de la Recherche (ANR) MALZ 2011 call for proposals and will be involved in the PREVENTAD project coordinated by the UMR7259 laboratory (Coordinator, Dr. Michel Khrestchatisky).
This (…)


Fourth round of financing

VECT-HORUS has completed a fourth round of venture capital funding from private shareholders.


Vect-Horus is a partner laureate of the ANR MALZ 2010 call for proposals

VECT-HORUS is a partner laureate of the Agence Nationale de la Recherche (ANR) MALZ 2010 call for proposals and will be involved in the ADHOC project coordinated by the UMR7259 laboratory (Coordinator, Pr. François Féron).
This project received (…)